发布求助
文献互助 智能选刊 最新文献

Pharma-Kritik最新文献

筛选
英文 中文
Unerwünscht 不需要的
Pharma-Kritik Pub Date : 2023-02-17 DOI: 10.37667/pk.2022.1231
E. Gysling
{"title":"Unerwünscht","authors":"E. Gysling","doi":"10.37667/pk.2022.1231","DOIUrl":"https://doi.org/10.37667/pk.2022.1231","url":null,"abstract":"<jats:p>N/A</jats:p>","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48031454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
tirbanibulin 替巴尼布林
Pharma-Kritik Pub Date : 2023-02-17 DOI: 10.18578/bnf.315609318
U. Masche
{"title":"tirbanibulin","authors":"U. Masche","doi":"10.18578/bnf.315609318","DOIUrl":"https://doi.org/10.18578/bnf.315609318","url":null,"abstract":"\u0000 Die Tirbanibulin-Salbe (Klisyri®) ist zur Behandlung von aktinischen Keratosen geeignet, relativ gut verträglich und muss nur kurz angewendet werden. Ob dieses Mittel ebenso wirksam ist wie z.B. Fluorouracil, wurde jedoch bisher nicht dokumentiert.    \u0000\u0000","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47581748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Gefapixant gepixant
Pharma-Kritik Pub Date : 2023-02-17 DOI: 10.37667/pk.2022.1225
N. Marty
{"title":"Gefapixant","authors":"N. Marty","doi":"10.37667/pk.2022.1225","DOIUrl":"https://doi.org/10.37667/pk.2022.1225","url":null,"abstract":"\u0000 \u0000Gefapixant (Lyfnua®) ist ein neuer Wirkstoff, mit dem einem Teil der Personen mit einem chronischen Husten geholfen werden kann. Das Medikament ist jedoch noch ungenügend dokumentiert und hat bei vielen Behandelten unerwünschte Wirkungen (insbesondere Störungen des Geschmacksinns). \u0000 \u0000\u0000","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45946077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirbanibulin 特尔巴尼布林
Pharma-Kritik Pub Date : 2023-02-17 DOI: 10.37667/pk.2022.1224
Urspeter Masche
{"title":"Tirbanibulin","authors":"Urspeter Masche","doi":"10.37667/pk.2022.1224","DOIUrl":"https://doi.org/10.37667/pk.2022.1224","url":null,"abstract":"Die Tirbanibulin-Salbe (Klisyri®) ist zur Behandlung von aktinischen Keratosen geeignet, relativ gut verträglich und muss nur kurz angewendet werden. Ob dieses Mittel ebenso wirksam ist wie z.B. Fluorouracil, wurde jedoch bisher nicht dokumentiert.","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135424104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ceterum censeo: Schmerzmittel 香炉：止痛药
Pharma-Kritik Pub Date : 2022-07-27 DOI: 10.37667/pk.2022.1205
E. Gysling
{"title":"ceterum censeo: Schmerzmittel","authors":"E. Gysling","doi":"10.37667/pk.2022.1205","DOIUrl":"https://doi.org/10.37667/pk.2022.1205","url":null,"abstract":"\u0000Leider gibt es nach wie vor keine gut wirksamen Schmerzmittel, die nicht auch bedeutsame Nebenwirkungen verursachen können. Bei der Behandlung von Schmerzen sollte man immer an nicht-medikamentöse Möglichkeiten denken.\u0000\u0000","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47102084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatotoxizität von Antimykotika 抗真菌药物的肝毒性
Pharma-Kritik Pub Date : 2022-07-26 DOI: 10.37667/pk.2022.1203
N. Marty
{"title":"Hepatotoxizität von Antimykotika","authors":"N. Marty","doi":"10.37667/pk.2022.1203","DOIUrl":"https://doi.org/10.37667/pk.2022.1203","url":null,"abstract":"<jats:p>N/A</jats:p>","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43197408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Verlust der Impulskontrolle 脉冲控制损失
Pharma-Kritik Pub Date : 2022-07-26 DOI: 10.37667/pk.2022.1201
E. Gysling
{"title":"Verlust der Impulskontrolle","authors":"E. Gysling","doi":"10.37667/pk.2022.1201","DOIUrl":"https://doi.org/10.37667/pk.2022.1201","url":null,"abstract":"\u0000 Neuere Neuroleptika wie z.B. Aripiprazol (Abilify® u.a.) können wie die bei Morbus Parkinson verwendeten Dopaminagonisten zu einem Verlust der Impulskontrolle (mit Spiel- oder Kaufsucht, Hyperphagie oder Hyper-sexualität) führen. \u0000\u0000 \u0000\u0000","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47358436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyreostatika relativ gut verträglich 胸脯寓意良好
Pharma-Kritik Pub Date : 2022-07-26 DOI: 10.37667/pk.2022.1202
E. Gysling
{"title":"Thyreostatika relativ gut verträglich","authors":"E. Gysling","doi":"10.37667/pk.2022.1202","DOIUrl":"https://doi.org/10.37667/pk.2022.1202","url":null,"abstract":"\u0000 \u0000In einer prospektiven Studie wurde untersucht, wie häufig das Thyreostatikum Thiamazol unerwünschte Wirkungen verursacht. Bei 25 von 208 Personen kam es zu einer Nebenwirkung meistens kutaner Natur; eine Agranulozytose oder eine hepatotoxische Wirkung wurde nicht beobachtet. Die Therapie mit Thyreostatika wird gesamthaft als gut verträgliche und kostengünstige Behandlung einer Basedow-Krankheit bezeichnet.\u0000 \u0000\u0000","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41870989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Herzinfarkte bei rheumatoider Arthritis auch unter Biologika-Therapie gehäuft 类风湿性关节炎的心脏病发作也在生物治疗下积累
Pharma-Kritik Pub Date : 2022-05-06 DOI: 10.37667/pk.2022.1196
E. Gysling
{"title":"Herzinfarkte bei rheumatoider Arthritis auch unter Biologika-Therapie gehäuft","authors":"E. Gysling","doi":"10.37667/pk.2022.1196","DOIUrl":"https://doi.org/10.37667/pk.2022.1196","url":null,"abstract":"\u0000Wer an einer rheumatoiden Arthritis leidet, hat ein erhöhtes kardiovaskuläres Risiko. Gemäss einer grossen Kohortenstudie sind koronare Ereignisse auch unter den heute oft verwendeten biologischen Basismedikamenten gehäuft. \u0000 \u0000\u0000","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48432489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Missbildungen wegen Metformin-Therapie des Vaters 由于父亲的药物
Pharma-Kritik Pub Date : 2022-05-06 DOI: 10.37667/pk.2022.1197
E. Gysling
{"title":"Missbildungen wegen Metformin-Therapie des Vaters","authors":"E. Gysling","doi":"10.37667/pk.2022.1197","DOIUrl":"https://doi.org/10.37667/pk.2022.1197","url":null,"abstract":"\u0000Wenn ein Mann während der Spermien-Entwicklungsphase (etwa die 3 Monate vor der Konzeption eines Kindes) mit Metformin behandelt wird, dann ist das Risiko von Missbildungen im Genitalbereich bei männlichen Nachkommen höher als in der Durchschnittsbevölkerung. \u0000\u0000","PeriodicalId":38760,"journal":{"name":"Pharma-Kritik","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41950213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信